Peter F. A. Mulders
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter F. A. Mulders has a total of 232 co-authors. Here are the top co-authors by number of shared publications:
- Sandra Heskamp
Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center
18 shared publications - Wim J. G. Oyen
Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, the Netherlands
18 shared publications - Carla Marie Louise van Herpen
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
17 shared publications - Ingrid M. E. Desar
Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands
17 shared publications - Winette T. A. van der Graaf
Netherlands Cancer Institute, Amsterdam, The Netherlands
17 shared publications - Adrienne H. Brouwers
Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
15 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Springer Nature in Tijdschrift voor Urologie
- Vol. 16 (S2) , S3-S18
Abstracts Najaarsvergadering NVU, 30 oktober 2026
Zelfkatheterisatie is de voorkeursbehandeling voor patiënten met urineretentie. De COMPaRE-trial toonde aan dat herbruikbare katheters even veilig zijn als eenmalige katheters. Langetermijnuitkomsten zijn nog onbekend.
- 9 October 2026
- Published by Springer Nature in Tijdschrift voor Urologie
- Vol. 16 (S2) , S3-S18
Open AccessAbstracts Najaarsvergadering NVU, 30 oktober 2026
Zelfkatheterisatie is de voorkeursbehandeling voor patiënten met urineretentie. De COMPaRE-trial toonde aan dat herbruikbare katheters even veilig zijn als eenmalige katheters. Langetermijnuitkomsten zijn nog onbekend.
- Open Access
- 9 October 2026
- Published by Springer Nature in Tijdschrift voor Urologie
- Vol. 16 (S2) , S1
Goede registratie leidt tot toenemend urologisch onderzoek
Samenvatting: Wetenschappelijk onderzoek door artsen wordt gekenmerkt door translationeel onderzoek. Iets wat onderzocht wordt op een researchafdeling wordt in de klinische praktijk getest.
- 9 October 2026
- Published by Springer Nature in Tijdschrift voor Urologie
- Vol. 16 (S2) , S1
Open AccessGoede registratie leidt tot toenemend urologisch onderzoek
Samenvatting: Wetenschappelijk onderzoek door artsen wordt gekenmerkt door translationeel onderzoek. Iets wat onderzocht wordt op een researchafdeling wordt in de klinische praktijk getest.
- Open Access
- 27 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2249
Impact of Heterogeneous DNA Methylation on the Accuracy of Quantitative Methylation-Specific PCR for Detecting DNA Hypermethylation in Prostate Cancer
DNA methylation is an epigenetic modification of the genome, with methylation-based biomarkers showing promise for cancer detection. Quantitative Methylation-Specific PCR (qMSP) is widely used to assess DNA methylation; however, its application to liquid biopsy samples presents technical challenges. Heterogeneity in methylation patterns may impact qMSP accuracy by reducing reliability. This study evaluated the impact of methylation heterogeneity on qMSP performance using synthetic DNA fragments mimicking methylation variation. Additionally, targeted methylation sequencing was performed on prostate cancer tissue and urine samples to examine methylation heterogeneity. The presence of unmethylated CpG sites within the primer and probe regions reduced fluorescence levels and increased Cp values, especially at the 3′-end of primers. The methylation sequencing of genomic DNA from prostate cancer tissue and urine samples revealed the presence of varying methylation patterns, correlating with qMSP outcomes. Tissue samples mainly exhibited fully methylated and fully unmethylated fragments, while urine samples consisted of a higher proportion of partly methylated fragments. The findings suggest that qMSP may not be a reliable method for methylation detection in samples with proportionally high levels of heterogeneous methylated fragments in contrast to fully methylated fragments. This highlights the need for improved DNA methylation analysis in liquid biopsy samples for clinical applications in cancer detection.
- 27 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2249
Open AccessImpact of Heterogeneous DNA Methylation on the Accuracy of Quantitative Methylation-Specific PCR for Detecting DNA Hypermethylation in Prostate Cancer
DNA methylation is an epigenetic modification of the genome, with methylation-based biomarkers showing promise for cancer detection. Quantitative Methylation-Specific PCR (qMSP) is widely used to assess DNA methylation; however, its application to liquid biopsy samples presents technical challenges. Heterogeneity in methylation patterns may impact qMSP accuracy by reducing reliability. This study evaluated the impact of methylation heterogeneity on qMSP performance using synthetic DNA fragments mimicking methylation variation. Additionally, targeted methylation sequencing was performed on prostate cancer tissue and urine samples to examine methylation heterogeneity. The presence of unmethylated CpG sites within the primer and probe regions reduced fluorescence levels and increased Cp values, especially at the 3′-end of primers. The methylation sequencing of genomic DNA from prostate cancer tissue and urine samples revealed the presence of varying methylation patterns, correlating with qMSP outcomes. Tissue samples mainly exhibited fully methylated and fully unmethylated fragments, while urine samples consisted of a higher proportion of partly methylated fragments. The findings suggest that qMSP may not be a reliable method for methylation detection in samples with proportionally high levels of heterogeneous methylated fragments in contrast to fully methylated fragments. This highlights the need for improved DNA methylation analysis in liquid biopsy samples for clinical applications in cancer detection.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Flow-chart patients according to RECIST-defined PD. *All patients had clinical disease progression; no CT-imaging was performed before initiation of systemic treatment ** In total 7 patients choose best supportive care. Three other patients underwent radiotherapy or surgery of all target lesions.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Flow-chart patients according to RECIST-defined PD. *All patients had clinical disease progression; no CT-imaging was performed before initiation of systemic treatment ** In total 7 patients choose best supportive care. Three other patients underwent radiotherapy or surgery of all target lesions.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Score chart with predicted probability (%) to remain on WW at 12 months This model was based on the number of IMDC Risk factors (0, 1, 2), the number or involved organ sites (0 - 4) and the geometric mean [¹⁸F]FDG SUVmax as a continuous variable. The underlying formula is 100*(exp(-0.531)^exp(0.198*[IMDC score] + 0.039*[No of affected organ sites] + 0.170*[geometric mean [¹⁸F]FDG SUVmax] - 1.09))
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Score chart with predicted probability (%) to remain on WW at 12 months This model was based on the number of IMDC Risk factors (0, 1, 2), the number or involved organ sites (0 - 4) and the geometric mean [¹⁸F]FDG SUVmax as a continuous variable. The underlying formula is 100*(exp(-0.531)^exp(0.198*[IMDC score] + 0.039*[No of affected organ sites] + 0.170*[geometric mean [¹⁸F]FDG SUVmax] - 1.09))
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Flow diagram of patient enrolment. * Four patients were unfit for systemic treatment due to clinical deterioration resulting from rapid disease progression (n=3) or comorbidity and age (n=1). Three other patients did not wat systemic treatment.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Flow diagram of patient enrolment. * Four patients were unfit for systemic treatment due to clinical deterioration resulting from rapid disease progression (n=3) or comorbidity and age (n=1). Three other patients did not wat systemic treatment.
- Open Access
- 4 November 2025
- Published by Springer Nature in Tijdschrift voor Urologie
- Vol. 15 (S2) , S1
Variatie wetenschappelijk onderzoek gegarandeerd
Samenvatting: De najaarsvergadering nadert weer en traditioneel worden de geselecteerde abstracts ook deze keer als een supplement gepubliceerd in het wetenschappelijk gedeelte van het Tijdschrift voor Urologie. Ik denk dat een eenieder kan profiteren van het feit dat deze nog steeds in papiervorm thuis worden afgeleverd.
- 4 November 2025
- Published by Springer Nature in Tijdschrift voor Urologie
- Vol. 15 (S2) , S1
Open AccessVariatie wetenschappelijk onderzoek gegarandeerd
Samenvatting: De najaarsvergadering nadert weer en traditioneel worden de geselecteerde abstracts ook deze keer als een supplement gepubliceerd in het wetenschappelijk gedeelte van het Tijdschrift voor Urologie. Ik denk dat een eenieder kan profiteren van het feit dat deze nog steeds in papiervorm thuis worden afgeleverd.
- Open Access
- 4 August 2025
- Published by Springer Nature in Tijdschrift voor Urologie
- Vol. 15 (5) , 87
Presentatie van zeldzame ziekten en de relatie van eUROGEN
- 4 August 2025
- Published by Springer Nature in Tijdschrift voor Urologie
- Vol. 15 (5) , 87
Open AccessPresentatie van zeldzame ziekten en de relatie van eUROGEN
- Open Access
- 23 May 2025
- Published by Springer Nature in Tijdschrift voor Urologie
- Vol. 15 (S1) , S1
Wetenschap op weg naar het hoge noorden
Samenvatting: Hier is alweer het volgende abstractnummer van het Tijdschrift voor Urologie. Deze keer van de voorjaarsvergadering van de NVU in Groningen. Martiniplaza is de plek waar veel urologen, arts-assistenten en arts-onderzoekers naartoe zullen gaan.
- 23 May 2025
- Published by Springer Nature in Tijdschrift voor Urologie
- Vol. 15 (S1) , S1
Open AccessWetenschap op weg naar het hoge noorden
Samenvatting: Hier is alweer het volgende abstractnummer van het Tijdschrift voor Urologie. Deze keer van de voorjaarsvergadering van de NVU in Groningen. Martiniplaza is de plek waar veel urologen, arts-assistenten en arts-onderzoekers naartoe zullen gaan.